Pin74 a New Way to Inform Decision-Maker and Enhance Vaccination Programs in Countries With Limited Budgets: The Case of Serbia

Sauboin, Christophe; Mihajlović, Jovan; Geets, R.; Antic, Djurdja; Standaert, BA

doi:10.1016/j.jval.2019.09.1315

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our recent experience in a Central European country convinced us that the combination of different tools such as CO portfolio with CEA was much more informative for the local NITAG [90]. The CO evaluation provided an overview of the immunisation benefits for different childhood diseases.…”

Section: Discussionmentioning

confidence: 99%

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future

Standaert

Sauboin

DeAntonio³

et al. 2020

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background:Cost-effectiveness analysis (CEA) is the economic analysis method most commonly applied today in the context of replacing one treatment with a new one in a developed healthcare system to improve efficiency. CEA is often requested by local healthcare decisionmakers to grant reimbursement.New preventative interventions, such as new vaccines, may however have much wider benefits inside and outside healthcare, when compared with treatment. These additional benefits include externalities on indirect clinical impact, reallocation of specific healthcare resources, improved quality of care, better productivity, better disease control, better fiscal revenues, and others. But these effects are sometimes difficult to integrate into a meaningful CEA result. They may appear as specific benefits for specific stakeholders, other than the stakeholders in healthcare.Objective: Based on a historical view about the application of economic assessments for vaccines our objective has been to make the inventory of who was/is interested in knowing the economic value of vaccines, in what those different stakeholders are likely to see the benefit from their perspective and how were/are we able to measure those benefits and to report them well. Results: The historical view disclosed a limited interest in the economic assessment of vaccines at start, more than 50 years ago, that was comparable to the assessment of looking for more efficiency in new industries through optimization exercises. Today, we are exposed to a very rich panoply of different stakeholders (n= 16). They have their specific interest in many different facets of the vaccine benefit of which some are well known in the conventional economic analysis (n=9), but most outcomes are hidden and not enough evaluated and reported (n=26). Meanwhile we discovered that many different methods of evaluation have been explored to facilitate the measurement and reporting of the benefits (n=18). Conclusion: Our recommendation for future economic evaluations of new vaccines is therefore to find the right combination among the three entities of stakeholder type selection, outcome measure of interest for each stakeholder, and the right method to apply. We present at the end examples that illustrate how successful this approach can be.

show abstract

Section: Discussionmentioning

confidence: 99%